Cyndeo Wealth Partners LLC Lowers Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Cyndeo Wealth Partners LLC lowered its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 25.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,726 shares of the medical research company's stock after selling 1,573 shares during the quarter. Cyndeo Wealth Partners LLC's holdings in Thermo Fisher Scientific were worth $2,352,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. LaFleur & Godfrey LLC grew its holdings in shares of Thermo Fisher Scientific by 9.1% during the 4th quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock valued at $15,486,000 after purchasing an additional 2,488 shares during the last quarter. Brighton Jones LLC grew its holdings in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares during the last quarter. Union Bancaire Privee UBP SA bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $71,877,000. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Finally, Bank Pictet & Cie Europe AG grew its holdings in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock valued at $79,677,000 after purchasing an additional 461 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 0.6%

Shares of NYSE TMO opened at $405.15 on Tuesday. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88. The stock has a market cap of $152.94 billion, a P/E ratio of 24.51, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. The firm has a 50-day moving average of $416.55 and a 200 day moving average of $491.11. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion during the quarter, compared to analysts' expectations of $10.23 billion. During the same period last year, the company posted $5.11 EPS. Thermo Fisher Scientific's revenue was up .2% on a year-over-year basis. As a group, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a yield of 0.42%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.09%.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on TMO. The Goldman Sachs Group set a $610.00 target price on shares of Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Argus cut their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Barclays cut their price target on shares of Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird cut their price target on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Finally, Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a report on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $605.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.